TABLE OF CONTENTS
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET 23
1.4 LIMITATIONS 24
1.5 MARKETS COVERED 24
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 33
2.7 PRODUCTS LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 MARKET APPLICATION COVERAGE GRID 36
2.11 VENDOR SHARE ANALYSIS 37
2.12 SECONDARY SOURCES 38
2.13 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 42
4.1 INTERNATIONAL STANDARDS 42
4.2 REGIONAL STANDARDS 42
4.3 MARKET VIEWPOINT OF KEY OPINION LEADERS 42
4.4 EXPECTATIONS OF FUTURE MARKET SCENARIOS 42
4.5 FINDINGS AND REGIONAL TRENDS 43
4.6 COMPETITIVE GROUPING 44
5 COUNTRY WISE- NO OF PROCEDURES 54
5.1 NORTH AMERICA 55
5.2 EUROPE 56
5.3 ASIA-PACIFIC 57
5.4 SOUTH AMERICA 58
5.5 MIDDLE EAST AND AFRICA 59
6 REGULATION 60
6.1 UNITED STATES 60
6.2 EUROPE 61
6.3 CHINA 62
6.4 AUSTRALIA 62
7 MARKET OVERVIEW 64
7.1 DRIVERS 66
7.1.1 INCREASE IN THE GERIATRIC POPULATION 66
7.1.2 RISE IN INCIDENCE OF GLAUCOMA ACROSS THE WORLD 66
7.1.3 GOVERNMENT INITIATIVES TO INCREASE AWARENESS ABOUT THE PREVENTION OF BLINDNESS 67
7.1.4 GROWTH IN POPULARITY OF MINIMALLY INVASIVE SURGERY ACROSS THE GLOBE 67
7.2 RESTRAINTS 68
7.2.1 INADEQUATE REIMBURSEMENT SCENARIO 68
7.2.2 STRINGENT REGULATIONS FOR MIGS DEVICES 68
7.2.3 HIGH COST OF SURGICAL PROCEDURES 68
7.3 OPPORTUNITIES 69
7.3.1 RAPID TRANSITION FROM GLAUCOMA MEDICATION TO MINIMALLY INVASIVE GLAUCOMA SURGERIES 69
7.3.2 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCT 69
7.4 CHALLENGES 70
7.4.1 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE 70
7.4.2 RISKS ASSOCIATED WITH THE MICRO INVASIVE GLAUCOMA SURGERY 71
8 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY PRODUCT 72
8.1 OVERVIEW 73
8.2 MIGS STENTS 76
8.3 MIGS SHUNTS 76
8.4 OTHERS 77
9 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY TARGET 78
9.1 OVERVIEW 79
9.2 TRABECULAR MESHWORK 82
9.3 SUPRACHOROIDAL SPACE 82
9.4 SUBCONJUNCTIVAL FILTRATION 83
9.5 REDUCING AQUEOUS PRODUCTION 84
10 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY SURGERY TYPE 85
10.1 OVERVIEW 86
10.2 GLAUCOMA IN CONJUNCTION WITH CATARACT 89
10.3 STAND-ALONE GLAUCOMA 89
11 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY END USER 91
11.1 OVERVIEW 92
11.2 HOSPITAL 95
11.3 OPHTHALMOLOGY CLINICS 95
11.4 AMBULATORY SURGERY CENTERS (ASCS) 96
11.5 OTHERS 97
12 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY DISTRIBUTION CHANNEL 98
12.1 OVERVIEW 99
12.2 DIRECT TENDER 102
12.3 RETAIL SALES 102
13 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET, BY REGION 104
13.1 OVERVIEW 105
13.2 NORTH AMERICA 110
13.2.1 U.S. 116
13.2.2 CANADA 118
13.2.3 MEXICO 120
13.3 EUROPE 122
13.3.1 GERMANY 128
13.3.2 FRANCE 130
13.3.3 U.K. 132
13.3.4 ITALY 134
13.3.5 SPAIN 136
13.3.6 SWITZERLAND 138
13.3.7 NETHERLANDS 140
13.3.8 BELGIUM 142
13.3.9 RUSSIA 144
13.3.10 TURKEY 146
13.3.11 REST OF EUROPE 148
13.4 ASIA-PACIFIC 149
13.4.1 CHINA 155
13.4.2 JAPAN 157
13.4.3 INDIA 159
13.4.4 SOUTH KOREA 161
13.4.5 AUSTRALIA 163
13.4.6 SINGAPORE 165
13.4.7 THAILAND 167
13.4.8 MALAYSIA 169
13.4.9 INDONESIA 171
13.4.10 PHILIPPINES 173
13.4.11 REST OF ASIA-PACIFIC 175
13.5 SOUTH AMERICA 176
13.5.1 BRAZIL 182
13.5.2 ARGENTINA 184
13.5.3 REST OF SOUTH AMERICA 186
13.6 MIDDLE EAST AND AFRICA 187
13.6.1 SOUTH AFRICA 193
13.6.2 SAUDI ARABIA 195
13.6.3 U.A.E. 197
13.6.4 ISRAEL 199
13.6.5 EGYPT 201
13.6.6 REST OF MIDDLE EAST AND AFRICA 203
14 GLOBAL MICRO INVASIVE GLAUCOMA SURGERY (MIGS) DEVICES MARKET: COMPANY LANDSCAPE 204
14.1 COMPANY SHARE ANALYSIS: GLOBAL 204
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 205
14.3 COMPANY SHARE ANALYSIS: EUROPE 206
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 207
15 SWOT ANALYSIS 208
16 COMPANY PROFILE 209
16.1 GLAUKOS CORPORATION 209
16.1.1 COMPANY SNAPSHOT 209
16.1.2 REVENUE ANALYSIS 209
16.1.3 COMPANY SHARE ANALYSIS 210
16.1.4 PRODUCT PORTFOLIO 210
16.1.4.1 RECENT DEVELOPMENT 210
16.2 ALCON INC. 211
16.2.1 COMPANY SNAPSHOT 211
16.2.2 REVENUE ANALYSIS 211
16.2.3 COMPANY SHARE ANALYSIS 212
16.2.4 PRODUCT PORTFOLIO 212
16.2.4.1 RECENT DEVELOPMENTS 213
16.3 ABBVIE INC. 214
16.3.1 COMPANY SNAPSHOT 214
16.3.2 REVENUE ANALYSIS 214
16.3.3 COMPANY SHARE ANALYSIS 215
16.3.4 PRODUCT PORTFOLIO 215
16.3.4.1 RECENT DEVELOPMENT 215
16.4 JOHNSON & JOHNSON SURGICAL VISION, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON) 216
16.4.1 COMPANY SNAPSHOT 216
16.4.2 REVENUE ANALYSIS 216
16.4.3 COMPANY SHARE ANALYSIS 217
16.4.4 PRODUCT PORTFOLIO 217
16.4.4.1 RECENT DEVELOPMENT 217
16.5 SANTEN PHARMACEUTICAL CO., LTD. 218
16.5.1 COMPANY SNAPSHOT 218
16.5.2 REVENUE ANALYSIS 218
16.5.3 COMPANY SHARE ANALYSIS 219
16.5.4 PRODUCT PORTFOLIO 219
16.5.4.1 RECENT DEVELOPMENTS 219
16.6 BELKIN VISION, ISRAEL 221
16.6.1 COMPANY SNAPSHOT 221
16.6.2 PRODUCT PORTFOLIO 221
16.6.3 RECENT DEVELOPMENT 221
16.7 BVI 222
16.7.1 COMPANY SNAPSHOT 222
16.7.2 PRODUCT PORTFOLIO 222
16.7.2.1 RECENT DEVELOPMENTS 223
16.8 ELLEX INC. 224
16.8.1 COMPANY SNAPSHOT 224
16.8.2 PRODUCT PORTFOLIO 224
16.8.2.1 RECENT DEVELOPMENTS 224
16.9 IOPTIMA 225
16.9.1 COMPANY SNAPSHOT 225
16.9.2 PRODUCT PORTFOLIO 225
16.9.3 RECENT DEVELOPMENT 225
16.10 MICROSURGICAL TECHNOLOGY. (A SUBSIDIARY OF HALMA PLC) 226
16.10.1 COMPANY SNAPSHOT 226
16.10.2 PRODUCT PORTFOLIO 226
16.10.2.1 RECENT DEVELOPMENT 226
16.11 NEW WORLD MEDICAL, INC. 227
16.11.1 COMPANY SNAPSHOT 227
16.11.2 PRODUCT PORTFOLIO 227
16.11.2.1 RECENT DEVELOPMENTS 227
16.12 NOVA EYE MEDICAL LIMITED 228
16.12.1 COMPANY SNAPSHOT 228
16.12.2 REVENUE ANALYSIS 228
16.12.3 PRODUCT PORTFOLIO 229
16.12.3.1 RECENT DEVELOPMENTS 229
16.13 SIGHT SCIENCES. 230
16.13.1 COMPANY SNAPSHOT 230
16.13.2 REVENUE ANALYSIS 230
16.13.3 PRODUCT PORTFOLIO 231
16.13.3.1 RECENT DEVELOPMENTS 231
17 QUESTIONNAIRE 233
18 RELATED REPORTS 235

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.